Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BPH GlobalASX:BP8 12-1 Month Momentum % is N/A% as of Aug. 21, 2026. The stock has 6 warning signs investors should review. Among 1,015 Drug Manufacturers companies, BPH Global ranks worse than 98522.07% on this metric.
12-1 Month Momentum % is the total return of the stock from 12-month ago to 1-month ago. As of today (2026-08-21), BPH Global's 12-1 Month Momentum % is N/A%.
The industry rank for BPH Global's 12-1 Month Momentum % or its related term are showing as below:
ASX:BP8's 12-1 Month Momentum % is not ranked *
in the Drug Manufacturers industry.
Industry Median: -14.96 * Ranked among companies with meaningful 12-1 Month Momentum % only.
BPH Global (ASX:BP8) 12-1 Month Momentum % Explanation
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 12-1 Month Momentum % measures the total return to a stock over the past twelve months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
BPH Global 12-1 Month Momentum % Related Terms
ASX:BP8 vs ZTS: 12-1 Month Momentum % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, BPH Global's 12-1 Month Momentum %, along with its competitors' market caps and 12-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BPH Global 12-1 Month Momentum % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, BPH Global's 12-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where BPH Global's 12-1 Month Momentum % falls into.
BPH Global (ASX:BP8) 12-1 Month Momentum % Calculation
12-1 Month Momentum % is calculated as following:
12-1 Month Momentum %
=
( Price 1-month ago
/
Price 12-month ago
- 1 )
*
100 %
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BPH Global (ASX:BP8) has a 12-1 Month Momentum % of N/A% as of Aug. 21, 2026. 12-1 Month Momentum measures the total return of the stock from 12-month ago to 1-month ago. View historical data on BPH Global and its competitors. According to the industry distribution chart, BPH Global ranks #999999 out of 1015 companies in the Drug Manufacturers industry.
Is BPH Global's 12-1 Month Momentum % too high?
BPH Global's current 12-1 Month Momentum % is N/A%. Based on the distribution chart, BPH Global ranks #999999 out of 1015 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers.
How does BPH Global's 12-1 Month Momentum % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, BPH Global ranks #999999 out of 1015 companies for 12-1 Month Momentum %. This places BPH Global in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 12-1 Month Momentum % for a Drug Manufacturers company?
A good 12-1 Month Momentum % depends on the Drug Manufacturers industry context. However, 12-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 12-1 Month Momentum % mean?
A high 12-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 12-1 Month Momentum measures the total return of the stock from 12-month ago to 1-month ago. View historical data on BPH Global and its competitors. BPH Global's current 12-1 Month Momentum % is N/A%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BPH Global stock overvalued right now?
BPH Global (ASX:BP8) has a current 12-1 Month Momentum % of N/A%. The current 12-1 Month Momentum % is N/A%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 12-1 Month Momentum % calculated?
12-1 Month Momentum % is calculated from a company's financial statements. For BPH Global (ASX:BP8), the current 12-1 Month Momentum % is N/A% as of Aug. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
BPH Global Ltd is a plant-focused biotechnology company with a focus on producing foods, health, and cosmetic products that deliver Traditional Chinese Medicine (TCM)-based health outcomes. It focuses on the research, development, production, and commercialization of TCM products, including bird's nest, seaweeds, and sea plants, which serve as sustainable plant-based protein sources and ingredients for food, nutrition, healthcare, cosmetics, and personal care industries. The company's geographical segment includes Australia, Indonesia, and China. The company's products comprise raw and processed bird's nest, sea grapes (Caulerpa lentillifera), and other seaweeds and sea plants.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:BP8 has been successfully added to your 
